Authors: Carolyn Y. Johnson April 27, 2022 The Washington Post Shortly after he served on a jury in March, Gregg Crumley developed a sore throat and congestion. The retired molecular biologist took a rapid test on a Saturday and saw a dark, thick line materialize — “wildly positive” for the coronavirus. Crumley, 71, contacted his […]
Authors: John Gibson the Brownstone Institute Pivotal randomized control trials (RCTs) underpinning approval of Covid-19 vaccines did not set out to, and did not, test if the vaccines prevent transmission of the SARS-CoV-2 virus. Nor did the trials test if the vaccines reduce mortality risk. A review of seven phase III trials, including those for Moderna, […]
Authors: Ravindra Kumar Garg1 and Vimal Kumar Paliwal2 Neuro 2022; 43(1): 3–40.Published online 2021 Oct 31. doi: 10.1007/s10072-021-05662-9PMCID: PMC8557950PMID: 34719776 Abstract COVID-19 vaccines have brought us a ray of hope to effectively fight against deadly pandemic of COVID-19 and hope to save lives. Many vaccines have been granted emergency use authorizations by many countries. Post-authorization, a wide spectrum of neurological complications […]
Authors: Zachary Stieb The Epoch Times March 9, 2022 Pfizer hired 600 employees in the months after its COVID-19 vaccine was authorized in the United States due to the “large increase” of reports of side effects linked to the vaccine, according to a document prepared by the company. Pfizer has “taken multiple actions to help […]
Authors: Yinon M. Bar-On, M.Sc., Yair Goldberg, Ph.D., Micha Mandel, Ph.D., Omri Bodenheimer, M.Sc., Ofra Amir, Ph.D., Laurence Freedman, Ph.D., Sharon Alroy-Preis, M.D., Nachman Ash, M.D., Amit Huppert, Ph.D., and Ron Milo, Ph.D. April 5, 2022 DOI: 10.1056/NEJMoa2201570 NEW ENGLAND JOURNAL OF MEDICINE Abstract BACKGROUND On January 2, 2022, Israel began administering a fourth dose of BNT162b2 vaccine to persons 60 years of age […]
Authors: Joseph Wilkinson, New York Daily NewsWed, April 6, 2022, 9:23 PM·2 min read A fourth shot of the Pfizer COVID-19 vaccine increased protection against viral infection for only four to seven weeks, according to a massive study published Tuesday. The study included 1.25 million people age 60 and over in Israel who received their […]
The I-TECH Randomized Clinical Trial February 18, 2022 Authors: Steven Chee Loon Lim, MRCP1; Chee Peng Hor, MSc2,3; Kim Heng Tay, MRCP4; et alAnilawati Mat Jelani, MMed5; Wen Hao Tan, MMed6; Hong Bee Ker, MRCP1; Ting Soo Chow, MRCP7; Masliza Zaid, MMed8; Wee Kooi Cheah, MRCP6; Han Hua Lim, MRCP9; Khairil Erwan Khalid, MRCP10; Joo Thye Cheng, MRCP2; Hazfadzila Mohd Unit, MRCP11; Noralfazita An, MMed12; Azraai Bahari Nasruddin, MRCP13; Lee Lee Low, MRCP14; Song Weng Ryan Khoo, MRCP15; Jia Hui Loh, MRCP16; Nor Zaila Zaidan, MMed17; Suhaila Ab Wahab, MMed18; Li Herng Song, MD19; Hui Moon Koh, MClinPharm20; Teck Long King, BPharm21; Nai Ming Lai, MRCPCH22; Suresh Kumar Chidambaram, MRCP4; Kalaiarasu M. Peariasamy, MSc23; for the I-TECH Study Group Article Information Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is […]
Authors: Alex Berenson New figures from Britain raise bright red flags about the direction of Covid in wealthy countries that used mRNA and DNA shots to attempt to defeat the coronavirus last year. Hospitalizations and deaths remain stubbornly high and overwhelmingly occur in vaccinated people. In February, 90 percent of the 1,000 Britons who died […]
Authors Meiling Lee THURSDAY, MAR 03, 2022 – 07:40 PM The messenger RNA (mRNA) from Pfizer’s COVID-19 vaccine is able to enter human liver cells and is converted into DNA, according to Swedish researchers at Lund University. The researchers found that when the mRNA vaccine enters the human liver cells, it triggers the cell’s DNA, […]
Authors: Wen Shi Lee, Adam K. Wheatley, Stephen J. Kent & Brandon J. DeKosky Nature Microbiology volume 5, pages1185–1191 (2020) Abstract Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). […]
